low - Healthcare utilization, particularly post-acute rehabilitation, is relatively non-discretionary and driven by medical necessity rather than economic conditions. However, elective orthopedic procedures (joint replacements) that feed rehabilitation admissions show modest correlation to consumer confidence and employment levels. Medicare patient volumes (70% of mix) are demographically driven by aging population trends rather than GDP growth.

Moderate sensitivity through two channels: (1) Valuation multiple compression as rising rates make defensive healthcare stocks less attractive relative to risk-free yields - typically trades at 12-15x EBITDA, which contracts 1-2 turns when 10-year Treasury exceeds 4.5%. (2) Modest impact on expansion financing costs for new hospital development, though the company maintains low leverage (0.08x Debt/Equity) and generates strong operating cash flow ($1.2B annually) to self-fund most growth capex. Refinancing risk is minimal given conservative capital structure.

growth - The company attracts growth-oriented healthcare investors seeking exposure to demographic tailwinds (aging population driving rehabilitation demand), consistent double-digit earnings growth (24% net income growth TTM), and strong returns on equity (22.6% ROE). The combination of 10%+ revenue growth, margin expansion potential, and capital deployment optionality (new hospital development, M&A, buybacks) appeals to investors willing to accept healthcare regulatory risk for above-market growth rates. Modest 3.9% FCF yield limits appeal to pure income investors.